Capitaland China Trust · SGX:AU8U
Capitaland China Trust — Q3 2025 Earnings Presentation
28 slides from Capitaland China Trust's earnings presentation, Oct 31, 2025
Slide 1: Q3 2025 Results
October 31, 2025 Q3 2025 Results Stephan B. Tanda, Aptar President and CEO Vanessa Kanu, Executive Vice President and CFO
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q3 2025 Financial Highlights
Q3 2025 Financial Highlights Q3 Highlights: 6% Q3 Reported Sales 1% • Aptar delivered solid third quarter results with strong product volume growth in Pharma and Closures Q3 Core Sales Growth* Growth • As we anticipated, we are seeing the steady ramp in sales for our injectables division, which grew
Slide 4: Recent Product and Technology Highlights
Recent Product and Technology Highlights Pharma Beauty Closures Custom Unidose System for Enbumyst Partnership with Dianosic to Award-Winning Fragrance Pump Decoration and - First U.S. FDA-Approved develop a bioresorbable Reloadable Airless for Prestige Fragrance Pump Clean & Intranasal Diuretic int
Slide 5: Recent Recognitions
Recent Recognitions Our award-winning commitment to sustainability is a competitive advantage that drives impact for our customers Forbes TIME CDP CDP EcoVadis Barron’s* Newsweek ISS ESG USA Today Le Point One of the One of the Climate A Recognized as a Sustainability Rating In the Top 100 In the To
Slide 6: Third Quarter 2025 Reported Results
Third Quarter 2025 Reported Results Q3 Reported Sales Q3 Reported EPS (in millions $) $1,200 $2.50 $1,000 6% $961 $1.92 $909 $2.00 30% $800 $1.48 $1.50 $600 $1.00 $400 $0.50 $200 $- $- Q3 2024 Q3 2025 Q3 2024 Q3 2025 +4% 23.8% 17.1% +1% Currency Effects Q3 2024 Q3 2025 Core Reported Reported Sales G
Slide 7: Third Quarter 2025 Adj. EPS and Adj. EBITDA
Third Quarter 2025 Adj. EPS and Adj. EBITDA Q3 Adjusted EPS* Q3 Adjusted EBITDA * (in millions $) $2.00 $280 $1.80 4% $1.62 $1.56 $1.60 $240 $223 $1.40 $208 7% $1.20 $200 $1.00 $0.80 $160 $0.60 $0.40 $120 $0.20 $- $80 Q3 2024 Q3 2025 $40 23.8% $- 20.8% Q3 2024 Q3 2025 Q3 2024 Q3 2025 Effective Tax E
Slide 8: Pharma Third Quarter 2025 Results
Pharma Third Quarter 2025 Results Q3 Sales Core Sales* Results by Market (in millions $) Adjusted EBITDA Margin % $500 40% $445 36.0% 37.2% • Prescription core sales increased 3% $450 $421 $400 Reported • Consumer Healthcare core sales decreased 11% $350 6% 30% • Injectables core sales increased 18%
Slide 9: Beauty Third Quarter 2025 Results
Beauty Third Quarter 2025 Results Q3 Sales Adjusted EBITDA Margin % Core Sales* by Market (in millions $) $360 16% $328 $320 $303 14% 13.3% • Fragrance, Facial Skin Care and Color Cosmetics core sales decreased 5% $280 Reported 12.1% 12% 8% • Personal Care core sales increased 13% $240 10% • Home Ca
Slide 10: Closures Third Quarter 2025 Results
Closures Third Quarter 2025 Results Q3 Sales Adjusted EBITDA Margin % Core Sales* by Market (in millions $) $200 $188 18% 17.2% $186 16.1% • Food core sales decreased 4% $180 16% Reported • Beverage core sales increased 9% $160 14% 1% $140 • Personal Care core sales decreased 8% 12% Core* $120 • Oth
Slide 11: Year-to-Date 2025 Reported Results
Year-to-Date 2025 Reported Results YTD Reported Sales YTD Reported EPS (in millions $) $3,500 $5.00 $4.75 $4.50 17% $3,000 $2,735 3% $2,814 $4.05 $4.00 $2,500 $3.50 $2,000 $3.00 $2.50 $1,500 $2.00 $1,000 $1.50 $1.00 $500 $0.50 $- $- YTD 2024 YTD 2025 YTD 2024 YTD 2025 +1% +1% Currency 22.7% 20.4% Ef
Slide 12: Year-to-Date 2025 Adj. EPS, Adj. EBITDA and Free Cash Flow
Year-to-Date 2025 Adj. EPS, Adj. EBITDA and Free Cash Flow YTD Adjusted EBITDA* Free Cash Flow* YTD Adjusted EPS* (in millions $) $700 $5.00 7% $4.48 8% $624 • $206 million for the first $4.50 $4.19 $580 $4.00 $600 nine months resulting $3.50 from cash from $500 $3.00 operations of $386 $2.50 $400 m
Slide 13: Outlook
Outlook Outlook Highlights Earnings Per Share • We expect our Pharma pipeline to remain strong and to continue to contribute 7% to 10% $1.80 of revenue annually, with new launches layered on to a stable base $1.63 $1.60 $1.49 • We also anticipate continued growth in injectables to be driven by accel
Slide 14: Appendix
Aptar.4 Appendix
Slide 15: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 15
Slide 16: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 16
Slide 17: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data) 17
Slide 18: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data) 18
Slide 19: Reconciliation of Reported to Core Sales
Reconciliation of Reported to Quarterly 2025 Reconciliation of Reported to Core Sales Growth Core Sales (rounded to the nearest whole percent) Growth by Active Market Material Third Quarter Segment Sales Analysis Prescription Consumer Science Digital Total (Rounded to the (Change over Prior Year) Dr
Slide 20: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 20
Slide 21: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 21
Slide 22: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands, Except Per Share Data) 22
Slide 23: Reconciliation of Adjusted EBIT After Taxes to Net Income
Reconciliation of Adjusted EBIT After Taxes to Net Income (Unaudited) ($ In Thousands) 23
Slide 24: Reconciliation of Capital to Stockholders' Equity
Reconciliation of Capital to Stockholders’ Equity (Unaudited) ($ In Thousands) 24
Slide 25: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 25
Slide 26: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) (Unaudited) (In Thousands) ($ In Thousands) Quarter to Date Year to Date 2025 2024 2025 2024 Net Cash Provided by Operations 177,606 229,262 386,306 465
Slide 27: Supplemental Information
Supplemental Information Quarterly 2025 Reconciliation of Reported to Core Sales Growth (rounded to the nearest whole percent) First Quarter Segment Sales Analysis Aptar Aptar Aptar Total (Change over Prior Year) Pharma Beauty Closures AptarGroup Total Reported Sales Growth 1% (7%) (5%) (3%) Currenc
Slide 28: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 28
CapitaLand China Trust — Q3 2025 Earnings Presentation on 6ix